Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 5/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.46 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25114312 | 0.90 | KDM4E (0.59) | SCN5AKDM4EPOLBRAB9AGAA | |
| SCHEMBL21033153 | 0.85 | GABRA2 (0.62) | KDM4EPOLBRAB9AEGLN1GAA | |
| SCHEMBL4083192 | 0.84 | KDM4E (0.60) | KDM4EPOLBRAB9AEGLN1GAA | |
| SCHEMBL3499130 | 0.83 | GABRA2 (0.62) | KDM4EPOLBRAB9AEGLN1GAA | |
| SCHEMBL21033466 | 0.81 | KDM4E (0.60) | KDM4EPOLBRAB9AEGLN1GAA | |
| SCHEMBL23645412 | 0.80 | KDM4E (0.55) | KDM4EPOLBRAB9AGAAGABRA2 | |
| SCHEMBL24066036 | 0.80 | KDM4E (0.60) | KDM4EPOLBRAB9AEGLN1GAA | |
| SCHEMBL21033565 | 0.79 | KDM4E (0.57) | KDM4EPOLBRAB9AEGLN1GAA | |
| SCHEMBL3883777 | 0.79 | KDM4E (0.60) | KDM4EPOLBRAB9AGAAGABRA2 | |
| SCHEMBL3663279 | 0.79 | KDM4E (0.57) | KDM4EPOLBRAB9AEGLN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | SCN5A 2695/4885KDM4E 2059/4885POLB 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.